Here, we found for the first time that GPX2 was upregulated in EGFR-TKI resistant NSCLC cells and tissues, accelerating the elimination of ROS and conferring drug resistance in NSCLC. The gene discussed is GPX2; the disease is non-small cell lung carcinoma.